EtoriCOXib 是一种合成的非甾体抗炎药 (NSAID)，具有解热、镇痛和潜在的抗肿瘤特性。它是可口服的选择性COX-2抑制剂，对人全血 COX-2 和 COX-1 的IC50值分别为 1.1 和 116 μM。

Etoricoxib is a synthetic, nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic, and potential antineoplastic properties. Etoricoxib specifically binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in inhibition of the conversion of arachidonic acid into prostaglandins. Inhibition of COX-2 may induce apoptosis and inhibit tumor cell proliferation and angiogenesis.

The preferential cyclooxygenase-2 inhibitor etoricoxib significantly reduces the anticonvulsant action of phenytoin and significantly increases the beneficial action of diazepam against maximal electroshock and pentylenetetrazole-induced convulsions in a mouse model[1]. Etoricoxib has the potential to act as an anti-apoptotic and anti- proliferative agent in the colon[2].

Human colon carcinoma cell line HCT-116 are treated with various coxibs for 2 h. Subsequently, the cells are harvested and the sphingolipids isolated and determined by LC-MS/MS. (Only for Reference)

202409-33-4

C18H15ClN2O2S

358.84

Tauxib;Desvenlafaxine;Arcoxia;MK-663;依托考昔;Nucoxia;L-791456

DMSO:66 mg/mL (183.9 mM)
H2O:<1 mgml
Ethanol:43 mg/mL (119.8 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years